BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Job Trends

  Catalent’s Momentum Continues with Up to 600 New Jobs Being Added

  Earlier this month, Catalent announced plans to add 500–600 jobs in Bloomington, Ind., one of its Moderna and Johnson & Johnson COVID-19 vaccine manufacturing sites.

  October 22, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Tryp Therapeutics Stumbles as FDA Halts Eating Disorder Study

  The FDA placed a clinical hold on Tryp Therapeutics’ Phase IIa trial for eating disorders, including binge eating disorder and hypothalamic obesity.

  October 22, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Gates MRI Signs On to Guide Atreca’s Malaria Antibody Home

  Atreca announced it is licensing its preclinical monoclonal antibody for the prevention of malaria to the Gates Medical Research Institute (MRI) for development.

  October 22, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  FDA

  Agenus Withdraws BLA for PD1 as Big Dog Merck Corners the Indication

  Lexington, Mass.-based Agenus withdrew its Biologics License Application for balstilimab from the U.S. FDA. The drug is a PD-1 inhibitor or checkpoint inhibitor.

  October 22, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Bio NC

  Clinical Catch-Up: October 18-22

  It was yet another busy week for clinical trial news. Here’s a look.

  October 22, 2021

   · 

  11 min read

   · 

  Mark Terry
• 

  Drug Development

  Smooth Sailing for Regeneron and LEO Pharma in Phase III

  Skin health logged major wins this week after two companies announced positive clinical trial results.

  October 22, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Athira Sets New Course After Leen Kawas is Ousted as CEO

  Late Thursday, Athira announced that Kawas had resigned from her position as CEO and president of the company.

  October 22, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Puts Ultimovac’s Cancer Vaccine Support Therapy on Fast Track

  The designation is based on data from two Phase I trials, which showed the drug to be safe, demonstrating early efficacy.

  October 22, 2021

   · 

  2 min read

   · 

  Kaylei Whalen
• 

  Policy

  Embattled Sabatini Fights Back Against Sexual Harassment Claim

  Two months after being ousted by the Whitehead Institute over allegations of sexual harassment, prominent cell biology researcher David Sabatini has filed a counter lawsuit.

  October 22, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  FDA

  FDA Action Alert: Pfizer-BioNTech, Oncopeptides, Eyenovia, ANI and More

  The U.S. FDA has a busy period at the end of October heading into the first week of November.

  October 22, 2021

   · 

  4 min read

   · 

  Mark Terry